![](https://endpts.com/wp-content/uploads/2021/12/Brian-Culley-1-scaled.jpg)
Brian Culley, Lineage Cell Therapeutics CEO
Lineage Cell Therapeutics opens new California R&D facility and expands Israel manufacturing site
Last year, Roche and Genentech paid $50 million for licensing rights to Lineage Cell Therapeutics’ OpRegen program, a cell therapy that looks to regenerate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.